Promising Prospects for PepGen Inc.: Buy Rating Affirmed Amid Positive DM1 Treatment Developments
H.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $16
Sell Rating on PepGen Inc. Amid Clinical and Regulatory Challenges
PepGen Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
PepGen Analyst Ratings
Stifel Maintains PepGen(PEPG.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (OtherPMCUF), PepGen Inc. (PEPG) and Idexx Laboratories (IDXX)
PepGen Price Target Cut to $16.00/Share From $26.00 by HC Wainwright & Co.
PepGen Analyst Ratings
Stifel Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $17
H.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Cuts Target Price to $16
PepGen Inc. (PEPG) Gets a Buy From Stifel Nicolaus
Wedbush Cuts Price Target on PepGen to $8 From $12, Maintains Outperform Rating
Leerink Partners Maintains PepGen(PEPG.US) With Buy Rating
BofA Securities Downgrades PepGen(PEPG.US) to Sell Rating, Cuts Target Price to $3
B of A Securities Maintains Neutral on PepGen, Lowers Price Target to $6
PepGen Inc. (PEPG) Receives a Buy From Stifel Nicolaus
PepGen Is Maintained at Outperform by Wedbush
H.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $26
Analysts Are Bullish on Top Healthcare Stocks: PepGen Inc. (PEPG), Ligand Pharma (LGND)